home / stock / mgnx / mgnx news

MGNX News and Press, MacroGenics Inc. From 05/05/20

Stock Information
Company Name: MacroGenics Inc.
Stock Symbol: MGNX
Market: NASDAQ
Website: macrogenics.com
Menu
MGNX MGNX Quote MGNX Short MGNX News MGNX Articles MGNX Message Board
Get MGNX Alerts

News, Short Squeeze, Breakout and More Instantly...
MGNX - MacroGenics' (MGNX) CEO Scott Koenig on Q1 2020 Results - Earnings Call Transcript

MacroGenics, Inc. (MGNX) Q1 2020 Earnings Conference Call May 5, 2020 04:30 PM ET Company Participants Anna Krassowska - VP, IR and Corporate Communications Scott Koenig - President and CEO Jim Karrels - SVP, CFO and Secretary Conference Call Participants Christopher Marai ...
MGNX - MacroGenics EPS beats by $0.11, beats on revenue

MacroGenics (NASDAQ: MGNX ): Q1 GAAP EPS of -$0.91 beats by $0.11 . More news on: MacroGenics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

MGNX - MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results

ROCKVILLE, Md., May 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progre...

MGNX - MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting

Rockville, MD, April 29, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced three clinical presentations...
MGNX - MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format

Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that its 2020 Annual Meeting...

MGNX - MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call

Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will releas...

MGNX - MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting

Rockville, MD, April 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced data related to flotetuzumab...
MGNX - ImmunoGen: Tremendous Value In Your Turnaround Stock

Bull markets are born on pessimism, grown on skepticism, mature on optimism and die on euphoria. - Sir John Templeton One of the best times for you to invest in a stock is when it tumbled far below its true worth. This usually occurs during a downturn like this Corona bear market. Howeve...

MGNX - Macrogenics Inc (MGNX) Q4 2019 Earnings Call Transcript

Image source: The Motley Fool. Macrogenics Inc   (NASDAQ: MGNX) Q4 2019 Earnings Call Feb 25, 2020 , 4:30 p.m. ET Operator Continue reading

MGNX - MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q4 2019 Results - Earnings Call Transcript

Start Time: 16:30 End Time: 17:23 MacroGenics, Inc. (MGNX) Q4 2019 Earnings Conference Call February 25, 2020, 16:30 PM ET Company Participants Scott Koenig - President and CEO Jim Karrels - SVP, CFO and Secretary Anna Krassowska - VP, IR and Corporate Communications Confe...
Previous 10 Next 10